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Anticancer activityA novel series of 4-methoxy, and 4,9-dimethoxy-5-substituted furo[2,3-g]-1,2,3-benzoxathi-
azine-7,7-dioxide derivatives3a,b, 10a–g and 11a–g were prepared in good yields via the reaction
of 4-methoxy (1a) and 4,7-dimethoxy-5-acetyl-6-hydroxybenzofurans (1b) and their a,b-unsat-
urated keto derivatives 6a–g and 7a–g with chlorosulfonyl isocyanate (CSI). On the other hand,
N-chlorosulfonyl carbamate derivatives 4a,b, 12a,b and 13a,b were prepared and allowed to
react with piperidine to give the corresponding N-piperidinosulfonyl carbamate derivatives
5a,b, 14a,b and 15a,b, respectively. Sixteen new target compounds 3a,b, 10a–g, and 11a–g were
tested for their DPPH radical-scavenging, and in vitro antiproliferative activity against A-549,
MCF7 and HCT-116 cancer cell lines. Compounds 10a, 11c, 11e, and 11g showed moderate
DPPH radical-scavenging activity compared to ascorbic acid at 100 lg/mL. 4,9-Dimethoxy-
5-substituted styrylfuro[3,2-g]-1,2,3-benzoxathiazine-7,7-dioxides 11a, 11b, and 11c were found
to be highly active against A-549 and HCT-116 cancer cell lines with IC50 values ranging from
0.02 to 0.08 lmol/mL compared to doxorubicin with IC50 = 0.04 and 0.06 lmol/mL,
respectively.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
Chlorosulfonyl isocyanate (CSI) is a remarkable reagent of
exceptional reactivity [1,2]. This reagent as a uniparticulate
electrophile and as a versatile heterocumulene is useful in many
synthetic transformations and in the synthesis of several
heterocyclic systems [3–7]. CSI undergoes nucleophilic addition
reaction with salicylaldehydes, 2-hydroxybenzophenones, and
2-hydroxychalcones in dry benzene at 0–5 C to afford
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of CSI with the above moieties in dry toluene at 100 C pro-
duces 1,2,3-benzoxathiazine 2,2-dioxides [5,7]. On the other
hand, benzofuran derivatives occupy signiﬁcance position due
to their widespread occurrence in plants [8] and for their biolog-
ical activities as antioxidant [9,10] and anticancer [11,12]. Based
on the above observations, our goal deals with study of the
reaction of CSI with 4-methoxy-5-acetyl-6-hydroxybenzofuran
(visnaginone) (1a), 4,7-dimethoxy-5-acetyl-6-hydroxybenzofu-
ran (khellinone) (1b), and their a,b-unsaturated keto deriva-
tives 6a–g and 7a–g to obtain novel furo[2,3-g]-1,2,3-
benzoxathiazine-7,7-dioxide derivatives and evaluating their
DPPH radical-scavenging and anticancer activities.
Experimental
Synthesis
Melting points were determined in open capillary tubes on an
Electrothermal 9100 digital melting point apparatus (Mount
Holly, New Jersey, USA) and were uncorrected. Elemental
analyses were performed on a Perkin-Elmer 2400 analyzer
(USA) and were found within ±0.4% of the theoretical values.
IR spectra were recorded on a Perkin-Elmer 1600 FTIR (USA)
in KBr disks. The NMR spectra were measured with a Bruker
Avance digital spectrometer (Germany) (500 and 125 MHz) in
DMSO-d6 and chemical shifts was recorded in d ppm relative
to TMS as internal standard. Mass spectra (EI) were run at
70 eV with a JEOL-JMS-AX500 mass spectrometer (Japan).
4-methoxy-5-acetyl-6-hydroxy benzofuran (visnaginone) (1a)
[13], 4,7-dimethoxy-5-acetyl-6-hydroxy benzofuran (khelli-
none) (1b) [14], a,b-unsaturated keto derivatives 6a–g and
7a–g [10,15,16] were prepared as reported.
Synthesis of compounds 2a and 2b
To a stirred solution of compound 1a or 1b (5 mmol) in dry
benzene (10 mL), was added a solution of chlorosulfonyl isocy-
anate (0.87 mL, 10 mmol) in dry benzene (5 mL) at 0–5 C
during 20 min and the stirring was continued for additional
1 h at the same temperature and then for 30 min at room tem-
perature. The reaction mixture was set aside at refrigerator
overnight. The solid that formed was ﬁltered off, air-dried,
and crystallized from benzene.
N-(4-Methoxy-6-(N-chlorosulfonyl carbamatobenzofuran-5-yl)
ethylidene)chlorosulfonyl amine 2a
R=H; m.p. 112–4 C; yield 44%. – IR (KBr): t= 3200
(NH), 1645 (C‚O), 1620 (C‚N), 1585 (C‚C), 1371, 1136
(SO2), 1121, 1119, 1110 (CAOAC), 740 cm
1 (Cl). – 1H
NMR (DMSO-d6) d: 1.61 (s, 3H, CH3), 4.20 (s, 3H, OCH3),
6.77 (s, 1H, H-7), 7.52 (d, 1H, H-3), 8.02 (s, 1H, NH), 8.21
(d, 1H, H-2). – 13C NMR (DMSO-d6) d: 20.2 (CH3), 60.9
(OCH3), 92.8–159.0 (ArAC), 166.6 (C‚N). –
C12H10Cl2N2O8S2 (445.25): calcd. C 32.37; H 2.26; N 6.29;
found C 32.15; H 2.11; N 6.47.
N-(4,7-Dimethoxy-6-(N-chlorosulfonyl carbamatobenzofuran-
5-yl) ethylidine)chlorosulfonyl amine 2b
R=OCH3; m.p 107–9 C; yield 32%. – IR (KBr): t= 3218
(NH), 1665 (C‚O), 1620 (C‚N), 1575 (C‚C), 1372, 1136(SO2), 1121, 1120, 1119, 1110 (CAOAC), 745 cm
1 (Cl). –
1H NMR (DMSO-d6) d: 1.99 (s, 3H, CH3), 4.01, 4.22 (2s,
6H, 2OCH3), 7.81 (d, 1H, H-3), 8.01 (s, 1H, NH), 8.23 (d,
1H, H-2). – 13C NMR (DMSO-d6) d: 21.8 (CH3), 61.0, 61.8
(OCH3), 105.6–151.3 (ArAC), 170.0 (C‚N). – C13H12Cl2N2
O9S2(475.28): calcd. C 32.85; H 2.54; N 5.89; found C 32.61;
H 2.30; N 5.64.
Synthesis of compounds 3a and 3b
Method A: cyclization of 2a and 2b
To a cold stirred solution of compounds 2a or 2b (10 mmol) in
dry dichloromethane (10 mL), a solution of triethylamine
(0.5 mL) in dry dichloromethane (2.5 mL) was added dropwise
during 5 min. The reaction mixture was stirred for 5 h at room
temperature. The solvent was evaporated in vacuo, and the
residue was triturated with acetone–water (1:10, 11 mL) and
allowed to stay for 1 h. The solution was neutralized by addi-
tion of 5% sodium hydrogen carbonate and the separated solid
was ﬁltered off, washed with water, air-dried, and crystallized
from absolute ethanol to give 3a (33%) or 3b (35%),
respectively.
Method B
To a stirred solution of compound 1a or 1b (10 mmol) in dry
toluene (40 mL), a solution of chlorosulfonyl isocyanate
(0.87 mL, 10 mmol) in dry toluene (5 mL) was added within
15 min. The reaction mixture was heated at 100–105 C for
3 h. Toluene was evaporated under vacuo, and the residue
was treated with cold water (50 mL). The solid that formed
was ﬁltered off, washed with water, air-dried, and crystallized
from absolute ethanol to give 3a (45%) or 3b (52%),
respectively.
4-Methoxy-5-methylfuro[3,2-g]-1,2,3-benzoxathiazine-7,7-
dioxide 3a . R=H; m.p. 161–3 C. – IR (KBr): t= 1620
(C‚N), 1579 (C‚C), 1375, 1165 (SO2), 1120, 1119, 1110 cm
1 (CAOAC). – 1H NMR (DMSO-d6) d: 2.89 (s, 3H, CH3),
4.40 (s, 3H, OCH3), 6.77 (s, 1H, H-9), 7.62 (d, 1H, H-3),
8.22 (d, 1H, H-2). – 13C NMR (DMSO-d6) d: 18.5 (CH3),
60.9 (OCH3), 92.8–159.0 (ArAC), 166.6 (C‚N). – EI-MS:
m/z (%) = 267 (M+, 100). – C11H9NO5S(267.26): calcd. C
49.43; H 3.39; N 5.24; found C 49.22; H 3.11; N 5.02.
4,9-Dimethoxy-5-methylfuro[3,2-g]-1,2,3-benzoxathiazine-7,7-
dioxide 3b. R= OCH3; m.p. 120–2 C. – IR (KBr): t= 1618
(C‚N), 1575 (C‚C), 1365, 1135 (SO2), 1120, 1119, 1110,
1009 cm1 (CAOAC). – 1H NMR (DMSO-d6) d: 2.81 (s, 3H,
CH3), 4.11, 4.32 (2s, 6H, 2OCH3), 7.61 (d, 1H, H-3), 8.22 (d,
1H, H-2). – 13C NMR (DMSO-d6) d: 28.8 (CH3), 61.0
(OCH3), 61.8 (OCH3), 105.6-151.3 (ArAC), 170.0 (C‚N). –
EI-MS: m/z (%) = 297 (M+, 100). – C12H11NO6S(297.28):
calcd. C 48.48; H 3.73; N 4.71; found C 48.23; H 3.69; N 4.55.
Synthesis of compounds 4a and 4b
To a stirred solution of compound 1a or 1b (10 mmol) in dry
benzene (10 mL), was added a solution of chlorosulfonyl isocy-
anate (0.87 mL, 10 mmol) in dry benzene (5 mL) at 0–5 C
during 20 min and the stirring was continued for additional
1 h at the same temperature and for 30 min at room tempera-
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night. The solid that formed was ﬁltered off, air-dried, and
crystallized from ethanol–water (10:1).
1-(4-Methoxy-6-(N-chlorosulfonyl carbamatobenzofuran-5-yl)
ethanone 4a
R=H; m.p. 100–2 C; yield 65%. – IR (KBr): t= 3128
(NH), 1730, 1645 (C‚O), 1600 (C‚C), 1375, 1157 (SO2),
1110, 1066, 1009 (CAOAC), 740 cm1 (Cl). – 1H NMR
(DMSO-d6) d: 2.91 (s, 3H, CH3), 3.99 (s, 3H, OCH3), 7.21
(s, 1H, H-7), 7.99 (s, 1H, H-3), 8.21 (d, 1H, H-2), 9.11 (s,
1H, NH).-C12H10ClNO7S(346.73): calcd. C 41.45; H 2.90; N
4.03; found C 41.22; H 3.01; N 3.99.
1-(4,7-Dimethoxy-6-(N-chlorosulfonyl carbamatobenzofuran-5-
yl) ethanone 4b
R= OCH3; m.p. 122–4 C; yield 55%. – IR (KBr): t= 3200
(NH), 1732, 1686 (C‚O), 1578 (C‚C), 1372, 1153 (SO2),
1111, 1099, 1066, 1001 cm1 (CAOAC). – 1H NMR
(DMSO-d6) d: 2.69 (s, 3H, CH3), 3.91, 4.21 (2s, 6H,
2OCH3), 7.01 (d, 1H, H-3), 8.22 (d, 1H, H-2), 8.91 (s, 1H,
NH). – C13H12ClNO8S(377.75): calcd. C 41.33; H 3.20; N
3.71; found C 41.11; H 3.22; N 3.56.
Synthesis of compounds 5a and 5b
A mixture of compounds 4a or 4b (10 mmol) and piperidine
(0.85 mL, 10 mmol) in dry 1,4-dioxane (20 mL) containing tri-
ethylamine (0.5 mL) was stirred at room temperature for 5 h
for compound 4a, 7 h for compound 4b, and then left over-
night at room temperature. The reaction mixture was poured
onto water and the precipitate that formed was ﬁltered off,
dried, and crystallized from methanol.
N-Piperidinosulfonyl-(4-methoxy-5-acetylbenzofuran-6-yl)
carbamate 5a
R=H; m.p. 220–2 C; yield 35%. – IR (KBr): t= 3128
(NH), 1725, 1678 (C‚O), 1575 (C‚C), 1370, 1152 (SO2),
1101, 1099, 1009 cm1 (CAOAC). – 1H NMR (DMSO-d6) d:
2.67 (s, 3H, CH3), 2.99–3.22 (m, 10H, piperidinyl), 3.91 (s,
3H, OCH3), 6.66 (s, 1H, H-7), 7.01 (d, 1H, H-3), 8.12 (d,
1H, H-2), 8.71 (s, 1H, NH). – C17H20N2O7S(396.41): calcd.
C 51.51; H 5.09; N 7.07; found C 51.32; H 5.21; N 6.99.
N-Piperidinosulfonyl-(4,7-dimethoxy-5-acetylbenzofuran-6-yl)
carbamate 5b
R= OCH3; m.p. 166–9 C; yield 42%. – IR (KBr): t= 3161
(NH), 1720, 1645 (C‚O), 1601 (C‚C), 1370, 1152 (SO2),
1112, 1099, 1066, 1009 cm1 (CAOAC). – 1H NMR
(DMSO-d6) d: 2.61 (s, 3H, CH3), 2.81–3.31 (m, 10H, piperidi-
nyl), 3.91, 4.21 (2s, 6H, 2OCH3), 7.61 (d, 1H, H-3), 8.12 (d,
1H, H-2), 9.51 (s, 1H, NH). – C18H22N2O8S(426.44): calcd.
C 50.70; H 5.20; N 6.57; found C 50.55; H 5.42; N 6.36.
Synthesis of compounds 8a and 9a
To a stirred solution of compound 6a or 7a (5 mmol) in dry
benzene (10 mL), was added a solution of chlorosulfonyl isocy-
anate (0.87 mL, 10 mmol) in dry benzene (5 mL) at 0–5 C
during 20 min and the stirring was continued for additional
1 h at the same temperature and then for 30 min at room tem-perature. The reaction mixture was set aside at refrigerator
overnight. The solid that formed was ﬁltered off, air-dried,
and crystallized from benzene.
N-[4-Methoxy-6-(N-chlorosulfonyl carbamatobenzofuran-5-
yl)-3-phenyl-prop-2-ene]chlorosulfonyl amine 8a
R=H; Ar‚C6H5; m.p. 120–2 C; yield 65%. – IR (KBr):
t= 3182 (NH), 1678 (C‚O), 1620 (C‚N), 1567 (C‚C),
1375, 1152 (SO2), 1111, 1066, 1009 (CAOAC), 750 cm
1
(Cl). – 1H NMR (DMSO-d6) d: 3.99 (s, 3H, OCH3), 6.66 (s,
1H, H-7), 7.11–7.31 (m, 5H, ArAH), 7.01, 7.66 (2d, 2H,
CH‚CH), 7.98 (d, 1H, H-3), 8.12 (d, 1H, H-2), 8.57 (s, 1H,
NH). – C19H14Cl2N2O8S2(533.36): calcd. C 42.79; H 2.65; N
5.25; found C 42.55; H 2.88; N 5.35.
N-[4,7-Dimethoxy-6-(N-chlorosulfonyl carbamatobenzofuran-
5-yl)-3-phenylprop-2-ene]chlorosulfonyl amine 9a
R= OCH3; Ar‚C6H5; m.p. 100–2 C; yield 60%. – IR (KBr):
t= 3200 (NH), 1645 (C‚O), 1618 (C‚N), 1575 (C‚C),
1370, 1150 (SO2), 1110, 1066, 1009, 1001 (CAOAC), 748 cm
1 (Cl). – 1H NMR (DMSO-d6) d: 3.99, 4.22 (2s, 6H,
2OCH3), 7.01–7.30 (m, 5H, phenyl), 7.66, 7.56 (2d, 2H,
CH‚CH), 7.98 (d, 1H, H-3), 8.12 (d, 1H, H-2), 9.55 (s, 1H,
NH). – C20H16Cl2N2O9S2(563.39): calcd. C 42.64; H 2.86; N
4.97; found C 42.44; H 3.01; N 5.10.
Synthesis of compounds 10a and 11a
Method A: cyclization of 8a and 9a
To a cold stirred solution of compound 8a or 9a (10 mmol) in
dry dichloromethane (10 mL), a solution of triethylamine
(0.5 mL) in dry dichloromethane (2.5 mL) was added dropwise
during 5 min. The reaction mixture was stirred for 5 h at room
temperature. The solvent was evaporated under vacuo, and the
residue was triturated with acetone–water (1:10, 11 mL) and
allowed to stay for 1 h. The solution was neutralized by addi-
tion of 5% sodium hydrogen carbonate, and the separated so-
lid was ﬁltered off, washed with water, air-dried, and
crystallized from absolute ethanol to give 10a (30%) or 11a
(32%), respectively.
Method B
To a stirred solution of compound 6a or 7a (10 mmol) in dry
toluene (40 mL), a solution of chlorosulfonyl isocyanate
(0.87 mL, 10 mmol) in dry toluene (5 mL) was added within
15 min. The reaction mixture was heated at 100–105 C for
3 h. Toluene was evaporated under vacuo and the residue
was triturated with cold water (50 mL). The solid that formed
was ﬁltered off, washed with water, air-dried, and crystallized
from absolute ethanol to give 10a (77%) or 11a (78%),
respectively.
4-Methoxy-5-styrylfuro[3,2-g]-1,2,3-benzoxathiazine-7,7-diox-
ide 10a . R=H; Ar‚C6H5; m.p. 92–4 C. – IR (KBr):
t= 1620 (C‚N), 1569 (C‚C), 1375,1145 (SO2), 1120,
1119, 1110 cm1 (CAOAC). – 1H NMR (DMSO-d6) d: 4.32
(s, 3H, OCH3), 6.88 (s, 1H, H-9), 7.01, 7.12 (2d, 2H,
CH‚CH), 7.32–7.68 (m, 5H, ArAH), 7.90 (d, 1H, H-3),
8.12 (d, 1H, H-2). – 13C NMR (DMSO-d6) d: 61.2 (OCH3),
96.3–155.2 (ArAC), 159.3 (C‚N). – EI-MS: m/z (%)=355
340 E.R. El-Sawy et al.(M+, 53). – C18H13NO5S(355.36): calcd. C 60.84; H 3.69; N
3.94; found C 60.66; H 3.54; N 3.77.
4,9-Dimethoxy-5-styrylfuro[3,2-g]-1,2,3-benzoxathiazine-7,7-
dioxide 11a. R=OCH3; Ar‚C6H5; m.p. 95–7 C. – IR (KBr):
t= 1620 (C‚N), 1598 (C‚C), 1375, 1135 (SO2), 1120, 1119,
1110, 1109 cm1 (CAOAC). – 1H NMR (DMSO-d6) d: 4.01,
4.22 (2s, 6H, 2OCH3), 7.01–733 (m, 5H, ArAH), 7.51, 7.61
(2d, 2H, CH‚CH), 7.89 (d, 1H, H-3), 8.24 (d, 1H, H-2). –
13C NMR (DMSO-d6) d: 61.6, 61.9 (2OCH3), 105.0–151.3
(ArAC), 172.0 (C‚N).-EI-MS: m/z (%) = 385 (M+, 75). –
C19H15NO6S(385.39): calcd. C 59.21; H 3.92; N 3.63; found
C 59.44; H 3.64; N 3.51.
Synthesis of compounds 10b–g and 11a–g
To a stirred solution of the appropriate a,b-unsaturated keto
derivatives 6b–g or 7b–g (10 mmol) in dry toluene (40 mL), a
solution of chlorosulfonyl isocyanate (0.87 mL, 10 mmol in
dry toluene 5 mL) was added during 15 min. The reaction mix-
ture was heated at 100–105 C for 3–4 h. Toluene was evapo-
rated under vacuo, and the residue was triturated with cold
water (50 mL). The solid that formed was ﬁltered off, washed
with water, air-dried, and crystallized from absolute ethanol.
4-Methoxy-5-(4-chlorostyryl)furo[3,2-g]-1,2,3-
benzoxathiazine-7,7-dioxide 10b
R=H; Ar‚C6H4Cl-p; m.p. 125–7 C; yield 52%. – IR (KBr):
t= 1620 (C‚N), 1599 (C‚C), 1375, 1155 (SO2), 1120, 1119,
1110 (CAOAC), 740 cm1 (Cl). – 1H NMR (DMSO-d6) d: 4.32
(s, 3H, OCH3), 6.77 (s, 1H, H-9), 7.00, 7.12 (2d, 2H,
CH‚CH), 7.21–7.76 (m, 4H, ArAH), 7.99 (d, 1H, H-3),
8.12 (d, 1H, H-2). – 13C NMR (DMSO-d6) d: 61.2 (OCH3),
96.2–131.1 (ArAC).-EI-MS: m/z (%) = 389/391 (M+/
M++2, 8/2). – C18H12ClNO5S (389.81): calcd. C 55.46; H
3.10; N 3.59; found C 55.33; H 3.22; N 3.34.
4-Methoxy-5-(4-ﬂuorostyryl)furo[3,2-g]-1,2,3-
benzoxathiazine-7,7-dioxide 10c
R=H; Ar‚C6H4F-p; m.p. 93–5 C; yield 42%. – IR (KBr):
t= 1620 (C‚N), 1601 (C‚C), 1375, 1145 (SO2), 1120,
1119, 1110 cm1 (CAOAC). – 1H NMR (DMSO-d6) d: 4.32
(s, 3H, OCH3), 6.77 (s, 1H, H-9), 7.01, 7.12 (2d, 2H,
CH‚CH), 7.31–7.68 (m, 4H, ArAH), 7.99 (d, 1H, H-3),
8.22 (d, 1H, H-2). – 13C NMR (DMSO-d6) d: 60.2 (OCH3),
92.8– 151.9 (ArAC).-EI-MS: m/z (%) = 373 (M+, 8). –
C18H12FNO5S(373.35): calcd. C 57.91; H 3.24; N 3.75; found
C 58.05; H 3.11; N 3.50.
4-Methoxy-5-(4-methoxystyryl)furo[3,2-g]-1,2,3-
benzoxathiazine-7,7-dioxide 10d
R=H; Ar‚C6H4OCH3-p; m.p. 162–4 C; yield 90%. – IR
(KBr): t= 1620 (C‚N), 1575 (C‚C), 1375, 1175 (SO2),
1120, 1119, 1110, 1009 cm1 (CAOAC). – 1H NMR
(DMSO-d6) d: 3.99, 4.30 (2s, 6H, 2OCH3), 6.77 (s, 1H, H-9),
7.01, 7.12 (2d, 2H, CH‚CH), 7.35–7.89 (m, 4H, ArAH),
7.99 (d, 1H, H-3), 8.24 (d, 1H, H-2). – 13C NMR (DMSO-
d6) d: 55.4, 61.2 (OCH3), 96.3–161.8 (ArAC), 172.3 (C‚N).
– EI-MS: m/z (%)=385 (M+, 40). – C19H15NO6S(385.39):
calcd. C 59.21; H 3.92; N 3.63; found C 59.01; H 4.00; N 3.55.4-Methoxy-5-(3,4,5-trimethoxystyryl)furo[3,2-g]-1,2,3-
benzoxathiazine-7,7-dioxide 10e
R=H; Ar‚C6H2(OCH3)3-3,4,5; m.p. 104–6 C; yield 97%. –
IR (KBr): t= 1620 (C‚N), 1589 (C‚C), 1375, 1175 (SO2),
1120, 1119, 1110, 1109, 1008 cm1 (CAOAC). – 1H NMR
(DMSO-d6) d: 3.89, 4.01, 4.12, 4.34 (4s, 12H, 4OCH3), 6.77
(s, 1H, H-9), 7.01, 7.32 (2d, 2H, CH‚CH), 7.55–7.89 (2d,
2H, ArAH), 7.99 (d, 1H, H-3), 8.24 (d, 1H, H-2). – 13C
NMR (DMSO-d6) d: 55.9, 59.9, 60.0, 61.0 (OCH3), 96.0–
159.2 (ArAC), 172.4 (C‚N). – EI-MS: m/z (%)=445 (M+,
43).-C21H19NO8S (445.44): calcd. C 56.62; H 4.30; N 3.14;
found C 56.44; H 4.11; N 3.30.
4-Methoxy-5-(4-N,N-dimethylstyryl)furo[3,2-g]-1,2,3-
benzoxathiazine-7,7-dioxide 10f
R=H; Ar‚C6H4N(CH3)2-p; m.p. 92–4 C; yield 98%. – IR
(KBr): t= 1618 (C‚N), 1599 (C‚C), 1375, 1135 (SO2),
1120, 1119, 1110 cm1 (CAOAC). – 1H NMR (DMSO-d6) d:
3.01, 3.12 (2s, 6H, 2CH3), 4.02 (s, 3H, OCH3), 6.77 (s, 1H,
H-9), 6.99, 7.12 (2d, 2H, CH‚CH), 7.24–7.57 (m, 4H, ArAH),
7.89 (d, 1H, H-3), 8.09 (d, 1H, H-2). – 13C NMR (DMSO-d6)
d: 60.0 (CH3), 61.1 (OCH3), 92.7–157.2 (ArAC), 170.0 (C‚N).
– EI-MS: m/z (%) = 398 (M+, 10). – C20H18N2O5S(398.43):
calcd. C 60.29; H 4.55; N 7.03; found C 60.11; H 4.35; N 7.21.
4-Methoxy-5-(2-(3-indolyl)vinyl)furo[3,2-g]-1,2,3-
benzoxathiazine-7,7-dioxide 10g
R=H; Ar = 3-indolyl; m.p. 134–6 C; yield 97%. – IR
(KBr): t= 3350 (NH), 1620 (C‚N), 1589 (C‚C), 1375,
1135 (SO2), 1120, 1119, 1110 cm
1 (CAOAC). – 1H NMR
(DMSO-d6) d: 4.22 (s, 3H, OCH3), 6.77 (s, 1H, H-9), 7.01,
7.12 (2d, 2H, CH‚CH), 7.24–7.57 (m, 4H, ArAH), 7.99 (s,
1H, indolyl 2-H), 8.12 (d, 1H, H-3), 8.34 (d, 1H, H-2), 9.91
(s, 1H, NH). – 13C NMR (DMSO-d6) d: 60.8 (OCH3), 105.8–
158.5 (ArAC), 107.0 (C‚N). – EI-MS: m/z (%) = 394 (M+,
1). – C20H14N2O5S(394.4): calcd. C 60.91; H 3.58; N 7.10;
found C 60.87; H 3.42; N 7.22.
4,9-Dimethoxy-5-(4-chlorostyryl)furo[3,2-g]-1,2,3-
benzoxathiazine-7,7-dioxide 11b
R=OCH3; Ar‚C6H4Cl-p; m.p. 113–5 C; yield 60%. – IR
(KBr): t= 1620 (C‚N), 1585 (C‚C), 1375, 1135 (SO2),
1120, 1119, 1110, 1009 (CAOAC), 740 cm1 (Cl). – 1H
NMR (DMSO-d6) d: 4.01, 4.22 (2s, 6H, 2OCH3), 6.97, 7.11
(2d, 2H, CH‚CH), 7.24–7.67 (m, 4H, Ar‚H), 7.99 (d, 1H,
H-3), 8.24 (d, 1H, H-2). – 13C NMR (DMSO-d6) d: 60.6,
60.9 (2OCH3), 105.0–152.8 (Ar‚C), 170.0 (C‚N). – EI-MS:
m/z (%)=419 (M+, 34). – C19H14ClNO6S(419.84): calcd. C
54.36; H 3.36; N 3.34; found C 54.44; H 3.11; N 3.12.
4,9-Dimethoxy-5-(4-ﬂuorostyryl)furo[3,2-g]-1,2,3-
benzoxathiazine-7,7-dioxide 11c
R=OCH3; Ar‚C6H4F-p; m.p. 130–2 C; yield 82%. – IR
(KBr): t= 1620 (C‚N), 1596 (C‚C), 1385, 1135 (SO2),
1120, 1119, 1110, 1009 cm1 (C‚O‚C). – 1H NMR
(DMSO-d6) d: 4.01, 4.22 (2s, 6H, 2OCH3), 7.21–7.37 (m, 4H,
Ar‚H), 7.51, 7.62 (2d, 2H, CH‚CH), 7.99 (d, 1H, H-3),
8.24 (d, 1H, H-2). – 13C NMR (DMSO-d6) d: 60.4, 60.9
(2OCH3), 105.5–152.6 (Ar‚C), 164.6 (C‚N). – EI-MS: m/z
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H 3.50; N 3.47; found C 56.44; H 3.35; N 3.24.
4,9-dimethoxy-5-(4-methoxystyryl)furo[3,2-g]-1,2,3-
benzoxathiazine-7,7-dioxide 11d
R= OCH3; Ar‚C6H4OCH3-p; m.p. 150 C dec.; yield 68%.
– IR (KBr): t= 1620 (C‚N), 1596 (C‚C), 1385, 1135
(SO2), 1120, 1119, 1110, 1009 cm
1 (C‚O‚C). – 1H NMR
(DMSO-d6) d: 3.88, 3.99, 4.20 (3s, 9H, 3OCH3), 7.01–7.39
(m, 4H, Ar‚H), 7.66, 7.72 (2d, 2H, CH‚CH), 7.99 (d, 1H,
H-3), 8.24 (d, 1H, H-2). – 13C NMR (DMSO-d6) d: 55.4,
61.6, 61.9 (OCH3), 106.2–151.1 (Ar‚C), 172.4 (C‚N). – EI-
MS: m/z (%) = 415 (M+, 62). – C20H17NO7S(415.42): calcd.
C 57.82; H 4.12; N 3.37; found C 57.65; H 4.22; N 3.11.
4,9-Dimethoxy-5-(3,4,5-trimethoxystyryl)furo[3,2-g]-1,2,3-
benzoxathi-azine-7,7-dioxide 11e
R= OCH3; Ar‚C6H2(OCH3)3-3,4,5; m.p. 120 C dec.; yield
72%. – IR (KBr): t= 1621 (C‚N), 1585 (C‚C), 1375,
1135 (SO2), 1120, 1118, 1110, 1109, 1009 cm
1 (C‚O‚C). –
1H NMR (DMSO-d6) d: 3.88, 3.99, 3.99, 4.01, 4.22 (5s, 15H,
5OCH3), 7.01 (s, 2H, Ar‚H), 7.52, 7.82 (2d, 2H, CH‚CH),
7.99 (d, 1H, H-3), 8.24 (d, 1H, H-2). – 13C NMR (DMSO-
d6) d: 55.6, 59.9, 60.0, 61.5, 62.7 (OCH3), 103.9–153.1 (Ar‚C).
– EI-MS: m/z (%) = 475 (M+, 11). – C22H21NO9S(475.47):
calcd. C 55.57; H 4.45; N 2.95; found C 55.44; H 4.22; N 2.77.
4,9-Dimethoxy-5-(4-N,N-dimethylstyryl)furo[3,2-g]-1,2,3-
benzoxathiazine-7,7-dioxide 11f
R= OCH3; Ar‚C6H4N(CH3)2-p; m.p. 86 C dec.; yield 93%.
– IR (KBr): t= 1620 (C‚N), 1589 (C‚C), 1375, 1135 (SO2),
1121, 1119, 1110, 1009 cm1 (C‚O‚C). – 1H NMR (DMSO-
d6) d: 2.31, 2.67 (2s, 6H, 2CH3), 4.01, 4.22 (2s, 6H, 2OCH3),
6.10, 6.31 (2d, 2H, CH‚CH), 7.67 (d, 1H, H-3), 8.24 (d,
1H, H-2). – 13C NMR (DMSO-d6) d: 21.0, 29.8 (CH3), 60.5,
61.8 (OCH3), 105.9–150.3 (Ar‚C), 170.0 (C‚N).-EI-MS:
m/z (%) = 428 (M+, 17). – C21H20N2O6S(428.46): calcd. C
58.87; H 4.70; N 6.54; found C 58.74; H 4.65; N 6.44.
4,9-Dimethoxy-5-(2-(3-indolyl)vinyl)furo[3,2-g]-1,2,3-
benzoxathiazine-7,7-dioxide 11g
R= OCH3; Ar = 3-indolyl; m.p. 129–31 C; yield 86%. – IR
(KBr): t= 3332 (NH), 1618 (C‚N), 1585 (C‚C), 1375, 1135
(SO2), 1121, 1119, 1110 cm
1 (C‚O‚C). – 1H NMR
(DMSO-d6) d: 3.99, 4.12 (2s, 6H, 2OCH3), 6.99, 7.12 (2d,
2H, CH‚CH), 7.21–7.47 (m, 4H, Ar‚H), 7.9 (s, indolyl 2-
H), 8.12 (d, 1H, H-3), 8.34 (d, 1H, H-2), 9.91 (s, 1H, NH). –
13C NMR (DMSO-d6) d: 60.5, 61.8 (OCH3), 105.9–150.3
(Ar‚C), 166.3 (C‚N). – EI-MS: m/z (%) = 424(M+, 1). –
C21H16N2O6S (424.43): calcd. C 59.43; H 3.80; N 6.60; found
C 59.22; H 3.65; N 6.45.
Synthesis of compounds 12a,b and 13a,b
To a stirred solution of the appropriate a,b-unsaturated keto
derivatives 6a, 6g, 7a or 7g (10 mmol) in dry benzene
(10 mL), was added a solution of chlorosulfonyl isocyanate
(0.87 mL, 10 mmol in dry benzene 5 mL) at 0–5 C during
20 min and the stirring was continued for additional 1 h atthe same temperature and for 30 min at room temperature.
The reaction mixture was set aside at refrigerator overnight.
The solid that formed was ﬁltered off, air-dried, and crystal-
lized from ethanol–water (10:1).
N-Chlorosulfonyl 4-methoxy-5-(3-phenylacryloyl)benzofuran-
6-yl carbamates 12a
R=H; Ar‚C6H5; m.p. 202–4 C; yield 70%. – IR (KBr):
t= 3180 (NH), 1720, 1645 (C‚O), 1545 (C‚C), 1370, 1150
(SO2), 1110, 1109, 1009 (C‚O‚C), 742 cm
1 (Cl). – 1H
NMR (DMSO-d6) d: 3.99 (s, 3H, OCH3), 6.66 (s, 1H, H-7),
7.21–7.45 (m, 5H, phenyl), 7.92 (d, 1H, H-3), 7.69, 7.71 (2d,
2H, CH‚CH), 8.12 (d, 1H, H-2), 9.71 (s, 1H, NH). –
C19H14ClNO7S(435.83): calcd. C 52.36; H 3.24; N 3.21; found
C 52.14; H 3.07; N 3.03.
N-Chlorosulfonyl 4-methoxy-5-(3-(3-
indolyl)acryloyl)benzofuran-6-yl carbamates 12b
R=H; Ar = 3-indolyl; m.p. 194–6 C; yield 75%. – IR
(KBr): t= 3280, 3218 (NH), 1702, 1665 (C‚O), 1575
(C‚C), 1370, 1151 (SO2), 1111, 1110, 1009 (C‚O‚C),
745 cm1 (Cl). – 1H NMR (DMSO-d6) d: 4.21 (s, 3H,
OCH3), 6.66 (s, 1H, H-7), 7.21–7.45 (m, 4H, indolyl), 7.12,
7.66 (2d, 2H, CH‚CH), 7.98 (d, 1H, H-3), 8.12 (d, 1H, H-
2), 8.25 (s, 1H, indolyl 2-H), 8.70 (s, 1H, NH), 9.71 (s, 1H,
indolyl NH). – C21H15ClN2O7S (474.87): calcd. C 53.11; H
3.18; N 5.90; found C 53.27; H 3.01; N 5.72.
N-Chlorosulfonyl 4,7-dimethoxy-5-(3-
phenylacryloyl)benzofuran-6-yl carbamates 13a
R= OCH3; Ar‚C6H5; m.p. 238–40 C; yield 70%. – IR
(KBr): t= 3180 (NH), 1730, 1670 (C‚O), 1575 (C‚C),
1370, 1157 (SO2), 1111, 1066, 1009, 1001 (C‚O‚C), 745 cm
1 (Cl). – 1H NMR (DMSO-d6) d: 3.99, 4.21 (2s, 6H,
2OCH3), 7.11–7.54 (m, 5H, phenyl), 7.66, 7.76 (2d, 2H,
CH‚CH), 7.91(d, 1H, H-3), 8.12 (d, 1H, H-2), 8.75 (s, 1H,
NH). – C20H16ClNO8S(465.86): calcd. C 51.56; H 3.46; N
3.01; found C 51.46; H 3.31; N 3.11.
N-Chlorosulfonyl 4,7-dimethoxy-5-(3-(3-indolyl)acryloyl)
benzofuran-6-yl carbamates 13b
R= OCH3; Ar = 3-indolyl; m.p. 141–3 C; yield 80%. – IR
(KBr): t= 3200, 3128 (NH), 1701, 1654 (C‚O), 1570
(C‚C), 1375, 1157 (SO2), 1111, 1099, 1066, 1001 (C‚O‚C),
745 cm1 (Cl). – 1H NMR (DMSO-d6) d: 3.91, 4.21(2s, 6H,
2OCH3), 7.21–7.45 (m, 4H, indolyl), 7.66, 7.79 (2d, 2H,
CH‚CH), 7.91 (d, 1H, H-3), 8.12 (d, 1H, H-2), 8.57 (s, 1H,
indolyl 2-H), 9.50 (s, 1H, NH), 10.51 (s, 1H, indolyl NH). –
C22H17ClN2O8S(504.90): calcd. C 52.33; H 3.39; N 5.55; found
C 52.21; H 3.30; N 5.42.
Synthesis of compounds 14a,b and 15a,b
A mixture of compounds 12a,b or 13a,b (10 mmol) and piper-
idine (0.85 mL, 10 mmol) in dry 1,4-dioxane (20 mL) contain-
ing triethylamine (0.5 mL) was stirred at room temperature for
5–7 h and then left overnight at room temperature. The reac-
tion mixture was poured onto water and the precipitate that
formed was ﬁltered off, dried, and crystallized from methanol.
342 E.R. El-Sawy et al.N-Piperidinosulfonyl 4-methoxy-5-(3-phenylacryloyl)
benzofuran-6-yl carbamates 14a
R=H; Ar‚C6H5; m.p. 78–80 C; yield 40%. – IR (KBr):
t= 3180 (NH), 1703, 1671 (C‚O), 1575 (C‚C), 1370, 1152
(SO2), 1009, 1000 cm
1 (C‚O‚C). – 1H NMR (DMSO-d6)
d: 2.66–3.21 (m, 10H, piperidinyl), 3.91 (s, 3H, OCH3), 6.67
(s, 1H, H-7), 7.01–7.22 (m, 5H, phenyl), 7.71, 7.79 (2d, 2H,
CH‚CH), 7.98 (d, 1H, H-3), 8.12 (d, 1H, H-2), 9.71 (s, 1H,
NH). – C24H24N2O7S(484.52): calcd. C 59.49; H 4.99; N
5.78; found C 59.32; H 4.85; N 5.64.N-Piperidinosulfonyl 4-methoxy-5-(3-(3-indolyl)acryloyl)
benzofuran-6-yl carbamates 14b
R=H; Ar = 3-indolyl; m.p. 262–4 C; yield 42%. – IR
(KBr): t= 3200, 3120 (NH), 1700, 1651 (C‚O), 1545
(C‚C), 1730, 1152 (SO2), 1111, 1009, 1000 cm
1 (C‚O‚C).
– 1H NMR (DMSO-d6) d: 2.61–3.22 (m, 10H, piperidinyl),
3.91 (s, 3H, OCH3), 6.61 (s, 1H, H-7), 7.11–7.45 (m, 4H, indo-
lyl), 7.71, 7.79 (2d, 2H, CH‚CH), 7.98 (d, 1H, H-3), 8.12 (d,
1H, H-2), 8.25 (s, 1H, indolyl 2-H), 8.71 (s, 1H, NH), 9.71 (s,
1H, indolyl NH). – C26H25N3O7S(523.56): calcd. C 59.65; H
4.81; N 8.03; found C 59.51; H 4.67; N 8.14.N-Piperidinosulfonyl 4,7-dimethoxy-5-(3-phenylacryloyl)
benzofuran-6-yl carbamates 15a
R=OCH3; Ar‚C6H5; m.p. 147–9 C; yield 55%. – IR (KBr):
t= 3187 (NH), 1701, 1645 (C‚O), 1560 (C‚C), 1375, 1152
(SO2), 1099, 1066, 1001 cm
1 (C‚O‚C). – 1H NMR
(DMSO-d6) d: 2.66–3.21 (m, 10H, piperidinyl), 3.91, 4.22 (2s,
6H, 2OCH3), 7.00–7.09 (m, 5H, phenyl), 7.71, 7.91 (2d, 2H,
CH‚CH), 7.98 (d, 1H, H-3), 8.12 (d, 1H, H-2), 9.71 (s, 1H,
NH). – C25H26N2O8S(514.55): calcd. C 58.36; H 5.09; N
5.44; found C 58.11; H 5.22; N 5.26.N-Piperidinosulfonyl 4,7-dimethoxy-5-(3-(3-indolyl)acryloyl)
benzofuran -6-yl carbamates 15b
R=OCH3; Ar = 3-indolyl; m.p. 91–3 C; yield 45%. – IR
(KBr): t= 3280, 3181 (NH), 1699, 1671 (C‚O), 1545
(C‚C), 1371, 1150 (SO2), 1111, 1009, 1000 cm
1 (C‚O‚C).
– 1H NMR (DMSO-d6) d: 2.61–3.22 (m, 10H, piperidinyl),
3.81, 4.11 (2s, 6H, 2OCH3), 7.11–7.45 (m, 4H, indolyl), 7.73,
7.71 (2d, 2H, CH‚CH), 7.98 (d, 1H, H-3), 8.12 (d, 1H, H-
2), 8.35 (s, 1H, indolyl 2-H), 8.79 (s, 1H, NH), 10.20 (s, 1H,
indolyl NH). – C27H27N3O8S(553.58): calcd. C 58.58; H 4.92;
N 7.59; found C 58.31; H 4.86; N 7.45.Biological assay
DPPH radical-scavenging activity
Sixteen new target synthesized compounds 3a,b, 10a–g, and
11a–g were screened for their DPPH radical-scavenging activ-
ity using the procedure of Viuda-Martos et al. [17]. A volume
of 20 lL of methanolic solution of test compounds of 100 lg/
mL was added to 2 mL of 6 · 105 mol L1 methanolic solu-
tion of DPPH (2.3659 mg DPPH in 100 mL methanol). The
mixture was shaken vigorously and allowed to stand for 1 hin a dark room. Ascorbic acid (Sigma–Aldrich Chemie GmeH,
Taufkirchen, Germany) was used as a reference. The decrease
in absorbance at 517 nm was determined using microplate
ELIZA reader (ASYS Hitech GmbH, Austria). Absorbance
of DPPH radical without sample was used as negative control.
The percentage of scavenging activity was calculated according
to the formula, % I= [(AB  As)/AB] · 100, where I=DPPH
inhibition%, AB = absorbance of control (t= 0 h) and
AS = absorbance of a tested sample at the end of the reaction
(t= 1 h). All tests and analyses were done in triplicate and the
results were averaged.
Cell culture
A-549 (human lung carcinoma), MCF7 (human breast carci-
noma), and HCT-116 (human colon carcinoma) cell lines were
obtained from Karolinska Institute, Stockholm, Sweden. All
cells were maintained in RPMI 1640 medium, except for A-
549 cancer cells which were maintained in DMEM medium
(Lonza Biowahittkar, Belgium). All the media were supple-
mented with 1% antibiotic–antimycotic mixture (10,000
U mL1 potassium penicillin, 10,000 lg/mL streptomycin sul-
fate, 25 lg/mL amphotericin B, and 1% L-glutamine (Biowest,
USA).
MTT cytotoxicity assay
Cell viability was investigated using MTT [3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide] (Bio Basic
Canada Inc., Canada) assay [18]. This reaction depends on
the mitochondrial reduction of yellow MTT into purple for-
mazan. All the preceding steps were carried out in sterile
laminar air ﬂow cabinet Biosafety class II level (Baker,
SG403INT, Sanford, ME, USA). All incubations were done
at 37 C in 5% CO2 incubator in humidiﬁed atmosphere
(Sheldon, TC2323, Cornelius, OR, USA). Cells were seeded
into 96-well microtiter plastic plates at the concentration of
(104 cells per well) and allowed to adhere for 24 h. Medium
was aspirated and fresh medium (without serum) was added
to the cells with various concentrations of the test com-
pounds (100, 50, 25, 12.5, 6.25, 3.12, 1.56, and 0.78 lg/mL
in DMSO) and incubated for 48 h. Medium was aspirated
and 40 lL MTT salt (2.5 lg/mL) was added to each well
and incubated for further 4 h. To stop the reaction and dis-
solve any formed formazan crystals, 200 lL of 10% sodium
dodecyl sulfate (SDS) was added to each well and incubated
overnight at 37 C. The amount of formazan product was
measured at 595 nm with a reference wavelength of 620 nm
as a background using a microplate reader (Bio-Rad Labo-
ratories, model 3350, USA). For the untreated cells (negative
control), medium was added instead of the test compounds.
A positive control Adrinamycin (doxorubicin)
(Mr = 579.9) was used as a known cytotoxic natural agent
giving 100% inhibition. Dimethyl sulfoxide (DMSO) was
the vehicle used for dissolution of tested compound, and
its ﬁnal concentration on the cells was less than 0.2%.
IC50 was calculated for the samples and negative control
(cells with vehicle) by the probit analysis using simple t-test
(SPSS statistical analysis software package/version 11.0, SPSS
Inc., (IL), Chicago, USA).
Scheme 1 Compounds 1–5, R, a=H; b=OCH3; reagents and conditions, (i) chlorosulfonyl isocyanate (CSI) (1:2 adduct), dry
benzene, 0–5 C; (ii) triethylamine, stirring; (iii) CSI (1:1 adduct), dry toluene, 100–105 C; (iv) CSI (1:1 adduct), dry benzene, 0–5 C; (v)
dry1,4-dioxane, triethylamine, r.t.
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Chemistry
The synthetic routes of the titled compounds are outlined in
Schemes 1 and 2. Addition of two equivalent of chlorosulfonyl
isocyanate (CSI) to 4-methoxy-5-acetyl-6-hydroxybenzofuran
(1a) and 4,7-dimethoxy-5-acetyl-6-hydroxybenzofuran (1b) in
dry benzene at 0–5 C led to the formation of N-(4-methoxy-
6-(N-chlorosulfonyl carbamate-benzofuran-5-yl)ethylidene)
chlorosulfonyl amine (2a) and N-(4,7-dimethoxy-6-(N-chloro-
sulfonyl carbamatobenzofuran-5-yl)ethylidine) chlorosulfonyl
amine (2b). Treatment of compound 2a or 2bwith triethylamine
under stirring afforded the cyclized, 4-methoxy-5-methylf-
uro[3,2-g]-1,2,3-benzoxathiazine-7,7-dioxide (3a) and 4,9-dime-
thoxy-5-methylfuro[3,2-g]-1,2,3-benzoxathiazine-7,7-dioxide
(3b) with overall yield 33 and 35%, respectively (method A).
This reaction probably proceeded through the intermediate A
followed by losing a molecule of (ClSO2NCO) as reported in
similar reactions [7] (Scheme 1).
On the other hand, cycloaddition reaction of CSI with com-
pounds 1a or 1b in dry toluene at 100–105 C (1:1 adduct) gave
a product identical in all aspects (mp, TLC and spectra) with
the cyclic 1,2,3-benzoxathiazine-7,7-dioxide derivatives 3a
and 3b with good yield of 45% and 52%, respectively (method
B). This reaction probably proceeded through the formation ofaryloxyisocyanate B followed by intramolecular [2 + 2] addi-
tion of C‚N group of the isocyanate to the C‚O group of
COCH3 with subsequent loss of carbon dioxide as reported
in similar reactions [7] (Scheme 1).
IR spectra of 3a and 3b showed no absorption bands for
C‚O and OH groups but showed absorption bands from
1135 to 1375 for SO2 group (c.f. experimental section). The IR
spectrum of compound 3a as an example showed absorption
bands at 1620, 1579, 1375, 1165, 1120, 1119, 1110 cm1. Its
1HNMR spectrum revealed signals at 2.89 (s, 3H, CH3), 4.40
(s, 3H, OCH3), 6.77 (s, 1H, H-9), 7.62 (d, 1H, H-3), 8.22 ppm
(d, 1H, H-2). Its 13C NMR spectrum revealed signals at 18.5
(CH3), 60.9 (OCH3), 92.8–159.0 (ArAC), 166.6 ppm (C‚N).
Moreover, reaction of CSI with compounds 1a or 1b in
equimolar amounts in dry benzene (1:1 adduct) at 0–5 C led
to the formation of 1-(4-methoxy-6-(N-chlorosulfonyl car-
bamatobenzofuran-5-yl) ethanone 4a and 1-(4,7-dimethoxy-
6-(N-chlorosulfonyl carbamatobenzofuran-5-yl) ethanone 4b,
respectively (Scheme 1). The structures of compounds 4a and
4b were conﬁrmed upon the bases of their correct elemental
analyses and spectral data (c.f. experimental section), besides
the chemical evidences that; (a) compounds 4a,b showed neg-
ative ferric chloride test and positive sulfur, nitrogen, and hal-
ogen tests and (b) compounds 4a,b reacted with piperidine in
presence of triethylamine and afforded the corresponding N-
piperidinosulfonyl carbamates 5a and 5b (Scheme 1).
Scheme 2 Compounds 6 and 10, R = H; Ar, a=C6H5, b=C6H4Cl-p, c=C6H4F-p, d=C6H4OCH3-p, e=C6H2(OCH3)3-3,4,5,
f=C6H4N(CH3)2-p, g= 3-indolyl; compounds 7 and 11, R = OCH3; Ar, a=C6H5, b=C6H4Cl-p, c=C6H4F-p, d=C6H4OCH3-p,
e=C6H2(OCH3)3-3,4,5, f=C6H4N(CH3)2-p, g= 3-indolyl; reagents and conditions; (i) chlorosulfonyl isocyanate (CSI) (1:2 adduct),
dry benzene, 0–5 C; (ii) triethylamine, stirring; (iii) CSI (1:1 adduct), dry toluene, 100–105 C; (iv) CSI (1:1 adduct), dry benzene, 0–5 C;
(v) dry1,4-dioxane, triethylamine, r.t.
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7a reacted with two equivalent of CSI in dry benzene at
0–5 C and gave N-(4-methoxy (8a) and (4,7-dimethoxy)-6-
(N-chlorosulfonylcarbamato-benzofuran-5-yl)-3-phenylprop-
2-ene)chlorosulfonyl amines (9a) with yields of 52% and 60%,
respectively. Cyclization of the latter compounds via their
reaction with triethylamine led to the formation of 4-methoxy
10a and 4,9-dimethoxy-5-styrylfuro[3,2-g]-1,2,3-benzoxathi-
azine-7,7-dioxide 11a with over all yields 30 and 32%, respec-
tively (Scheme 2).
Due to the low yield of compounds 10a and 11a via the
above two step reactions, we used the direct reaction of CSI
with compounds 6a or 7a in dry toluene at 100–105 C (1:1 ad-
duct) to give 10a and 11a with good yields 77% and 78%,
respectively (Scheme 2). Also, a,b-unsaturated keto derivatives
6b–g and 7b–g allowed to react with CSI under the above men-
tioned conditions to give the corresponding 4-methoxy-5-arylf-
uro[3,2-g]-1,2,3-benzoxathiazine-7,7-dioxide derivatives (10b–
g) and 4,9-dimethoxy-5-arylfuro[3,2-g]-1,2,3-benzoxathiazine-
7,7-dioxide derivatives (11b–g), respectively (Scheme 2) with
good yields ranging from 60% to 98%. IR (KBr) spectrum
of 10a as an example showed characteristic absorption bands
at 1620, 1569, 1375, 1145, 1120, 1119 and 1110 cm1. Its 1H
NMR spectrum revealed signals at 4.32 (s, 3H, OCH3), 6.88
(s, 1H, H-9), 7.01, 7.12 (2d, 2H, CH‚CH), 7.32–7.68 (m,5H, ArAH), 7.90 (d, 1H, H-3), 8.12 ppm (d, 1H, H-2). Its
13C NMR spectrum revealed signals at 61.2 (OCH3), 96.3–
155.2 (ArAC), 159.3 ppm (C‚N). Mass spectrum of 10a
showed molecular ion peak at m/z= 355 (53%) and base peak
at m/z= 190.
On the other hand, reaction of compounds 6a, 6g, 7a or 7g
with CSI in dry benzene (1:1 adduct) at 0–5 C afforded N-
chlorosulfonyl carbamato-a,b-unsaturated keto derivatives
12a,b and 13a,b, respectively (Scheme 2). The reaction of the
latter compounds 12a,b and 13a,b with piperidine in presence
of triethylamine afforded the corresponding N-piper-
idinosulfonyl carbamates 14a,b and 15a,b, respectively
(Scheme 2).
The structure of all the new compounds was conﬁrmed
based on their correct elemental analyses and spectral data
(c.f. experimental section).
Biological activity
DPPH radical-scavenging activity
Compounds 3a,b, 10a–g, and 11a–g were screened for their
DPPH radical-scavenging activity using ascorbic acid as a ref-
erence. Antioxidant reacts with DPPH, which is stable free
radical and converts it to 1,1-diphenyl-2-picrylhydrazine. The
Table 1 DPPH radical-scavenging assay of the synthesized
compounds.
Compd. Scavenging activity
(%)a at 100 lg/mL
3a 10.6
3b 30.4
10a 59.7
10b 12.7
10c 11.1
10d 7.5
10e 11.8
10f 0.0
10g 20.4
11a 17.4
11b 28.5
11c 50.3
11d 17.3
11e 50.0
11f 9.7
11g 53.8
Negative control –
Ascorbic acid 96.0
a Results are the mean of three independent experiments.
Table 2 Antiproliferative activity of the newly synthesized
compounds against human carcinoma cell lines.
Compd.a Inhibition growth (%)
A549 MCF7 HCT-116
3a 15.8 28.0 45.7
3b 4.2 36.0 0
10a 73.3 91.2 100
10b 82.7 99.2 100
10c 8.2 95.4 69.9
10d 4.9 85.4 74.8
10e 68.7 85.4 81.6
10f 21.4 27.2 4.3
10g 29.6 16.7 0
11a 81.0 84.4 100
11b 82.7 97.5 100
11c 73.8 92.2 100
11d 1.5 6.1 16.7
11e 55.2 80.2 88.0
11f 0 20.7 0
11g 0 0 1.4
Negativeb control – – –
Doxorubicin 100.0 100.0 100.0
a Concentration of test compounds and positive control (doxo-
rubicin) 100 lg/mL.
b Untreated cells in DMSO and its ﬁnal concentration on the cells
was less than 0.2%.
Table 3 IC50 of the highly antiproliferative active compounds
against human cancer cell lines.
Compd. IC50 (lmol/mL)
A549 MCF7 HCT-116
10a >0.78 >0.78 >0.78
10b >0.78 >0.78 >0.78
11a 0.05 >0.78 0.08
11b 0.03 >0.78 0.05
11c 0.02 >0.78 0.03
11e – >0.78 >0.78
Doxorubicin 0.04 0.07 0.06
IC50. – Concentration required inhibiting cell viability by 50%.
IC50. – >0.78 is considered inactive.
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the antioxidant compounds. From the data obtained, only
compounds 10a, 11c, 11e, and 11g showed moderate DPPH
radical-scavenging activity of 59.7%, 50.3%, 50.0% and
53.8%, respectively, than the rest of the screened compounds,
which showed slightly activity compared to ascorbic acid of
96.0% at 100 lg/mL, Table 1.Antiproliferative activity
Compounds 3a,b, 10a–g, and 11a–g were preliminary screened
for their in vitro antiproliferative activity against human lung
carcinoma (A-549), human breast cancer (MCF7), and human
colon cancer (HCT-116) cell lines at a concentration of 100 lg/
mL, Table 2. Compounds 10a, 10b, 11a, 11b, and 11c were
found to be the most active compounds with antiproliferative
activity of 100% against HCT-116 cancer cell line, whereas the
most active compounds against MCF7 cancer cell line was in
the descending order of 10b> 11b> 10c> 11c> 10a> 10d
and 10e with antiproliferative activity of 99.2%, 97.5%,
95.4%, 92.2%, 91.2%, 85.4% and 85.4%, respectively. On
the other hand, compounds 10a, 10b,11a, 11b, and 11c were
found to be the most active one with antiproliferative activity
of 73.3%, 82.7%, 81.0%, 82.7%, and 73.8%, respectively,
against A-549 cancer cell line.
The compounds that showed antiproliferative activity
higher than 70% at concentration of 100 lg/mL were used to
calculate their IC50 value, which corresponds to the concentra-
tion required for 50% inhibition of cell viability. Doxorubicin
was used as a reference drug, Table 3. From the data obtained,
compound 11a showed potent inhibition of IC50 = 0.05 and
0.08 lmol/mL against A-549 and HCT-116, respectively,
nearly as active as doxorubicin of IC50 = 0.04 and 0.06
lmol/mL, respectively.
On the other hand, compounds 11b and 11c showed higher
activity with inhibition of IC50 = 0.03 and 0.02 lmol/mL,
respectively, against A-549 compared to doxorubicin (IC50 =
0.04 lmol/mL). Also, compounds 11b and 11c showed higher
activity with inhibition of IC50 = 0.05 and 0.03 lmol/mL,
respectively, against HCT-116 compared to doxorubicin
(IC50 = 0.06 lmol/mL.
From the data obtained, it is clear that compounds 11a,
11b, and 11c found to be the most active compounds against
A-549 and HCT-116 cancer cell lines and their activity may
be due to the presence of the methoxy donating group at the
position-9 of furobenzoxathiazine. Besides that, the presence
of withdrawing chlorine atom in 11b and ﬂuorine atom in
11c at the Para position of phenyl ring improved their activi-
ties toward A-549 and HCT-116 cancer cell lines.
Conclusions
A novel series of 4-methoxy, and 4,9-dimethoxy-5-substituted
furo[2,3-g]-1,2,3-benzoxathiazine-7,7-dioxide derivatives 3a,b,
346 E.R. El-Sawy et al.10a–g and 11a–g were prepared via reaction of 4-methoxy (1a)
and 4,7-dimethoxy-5-acetyl-6-hydroxy benzofurans (1b) and
their a,b-unsaturated keto derivatives 6a–g and 7a–g with
chlorosulfonyl isocyanate (CSI). Compounds 10a, 11c, 11e,
and 11g showed moderate DPPH radical-scavenging activity
compared to ascorbic acid at 100 lg/mL. 4,9-Dimethoxy-5-
substituted styrylfuro[3,2-g]-1,2,3-benzoxathiazine-7,7-diox-
ides 11a, 11b, and 11c were found to be highly active against
A-549 and HCT-116 cancer cell lines with IC50 values ranging
from 0.02 to 0.08 lmol/mL compared to doxorubicin of
IC50 = 0.04 and 0.06 lmol/mL, respectively.
Conﬂict of interest
The authors have declared no conﬂict of interest.Acknowledgments
The authors are grateful to Micro-analytical Unit, National
Research Centre, Cairo, Egypt, for carrying out elemental
analyses and IR spectra. Also, the authors thank Kamel H.
Shaker and NMR/Biosynthesis Department, Max Plank Insti-
tute for Chemical Ecology 07745, Jena, Germany, for carrying
out NMR and mass spectra.
References
[1] Dhar DN, Murthy KSK. Recent advances in the chemistry of
chlorosulfonyl isocyanate. Synthesis 1986:437–49.
[2] Rasmussen JK, Hassner A. Recent development in the synthetic
of chlorosulfonyl isocyanate. Chem Rev 1976;76:389–408.
[3] Suschitzky H, Walrond R, Hull R. Synthesis of heterocyclic
compounds. Part 34: Reactions of chlorosulfonyl isocyanate
with carbon–nitrogen double bonds. J Chem Soc Perkin Trans
1977;1:47–52.
[4] Dhar DN, Raghunathan R. Reaction of chlorosulphonyl
isocyanate with 2-pyrazolines. Ind J Chem 1984;23B:1187–9.
[5] Kamal A, Sattur PB. Reactions with chlorosulfonyl isocyanate:
formation of 2H–1,3-benzoxazine-2-ones. Synth Commun
1982;12:157–62.
[6] Hollwood F, Suschitzky H, Hull R. Chlorosulfonyl isocyanate
addition to o-dialkylaminostyrenes: preparation of 6-(o-
dialkylaminophenyl)-uracils. Synthesis 1982;2:662–5.[7] Dhar DN, Bag AK. Synthesis of 4-styryl-1,2,3-benzoxathiazine
2,2-dioxides, naphtha[1,2-e]-1,2,3-oxathiazine 2,2-dioxide & 1,3-
dipolar cycloaddition of 1,3-diphenylnitrilimine to 4-styryl-
1,2,3-benzoxathiazine 2,2-dioxides. Ind J Chem
1983;22B:627–31.
[8] Liu J, Dumontet V, Simonin A, Iorga BI, Guerineau V,
Litaudon MV, et al. Benzofurans from Styrax agrestis as
acetylcholinesterase Inhibitors: structure activity relationships
and molecular modeling studies. J Nat Prod 2011;74:2081–8.
[9] Rindhe SS, Rode MA, Karale BK. New benzofuran derivatives
as an antioxidant agent. Indian J Pharm Sci 2010;72:231–5.
[10] Patil SL, Bhalgat CM, Burli S, Chithale SK. Synthesis,
antibacterial and antioxidant properties of newer 3-(1-
benzofuran-2-yl)-5-substituted aryl-1, 2-oxazole. Int J Chem
Sci App 2010;1:42–9.
[11] Parekh S, Bhavsar D, Savant M, Thakrar S, Bavishi A, Parmar
M, et al. Synthesis of some novel benzofuran-2-yl(4,5-dihyro-
3,5-substituted diphenylpyrazol-1-yl) methanones and studies on
the antiproliferative effects and reversal of multidrug resistance
of human MDR1-gene transfected mouse lymphoma cells in
vitro. Eur J Med Chem 2011;46:1942–8.
[12] El-Nakkady SS, Roaiah HF, El-Serwy WS, Soliman AM, El-
Moez SI, Abdel-Rahman AA. Antitumor and antimicrobial
activities of some hetero aromatic benzofurans derived from
naturally occurring visnagin. Acta Pol Pharm 2012;69:645–55.
[13] Spath E, Gruber W. Natural chromones II. Constitution of
visnagin (from Ammi visnaga). Ber Dtsch Chem Ges
1941;74B:1492–500.
[14] Schonberg A, Sina A. Khellin and allied compounds. J Am
Chem Soc 1950;72:1611–5.
[15] Schonberg A, Sina A. On visnagin and khellin and related
compounds. Simple synthesis of chromons. J Am Chem Soc
1950;72:3396–9.
[16] Schonberg A, Badran N, Strawkawksy N. Furo-chromones and
coumarins. VII. Degradation of visnagin, khellin and related
substances; experiments with chromic acid and hydrogen
peroxide; and a synthesis of Eugenitin. J Am Chem Soc
1953;75:4992–5.
[17] Viuda-Martos M, El Gendy AE, Sendra E, Ferna´ndez-Lo´pez J,
Abd El Razik KA, Omer EA, et al. Chemical composition and
antioxidant and anti-Listeria activities of essential oils obtained
from some Egyptian plants. J Agric Food Chem
2010;58:9063–70.
[18] Mosmann T. Rapid colorimetric assay for cellular growth and
survival: application to proliferation and cytotoxicity assays. J
Immunol Meth 1983;65:55–63.
